Edaravone (Radicava) and ALS (Amyotrophic Lateral Sclerosis): Latest Research 2026

By Insight Swarm Research Team, Medical Advisor: Nikhil Joshi, MD, FRCPC

Edaravone (Radicava) and ALS (Amyotrophic Lateral Sclerosis): Latest Research 2026

This page summarizes the current state of scientific research on Edaravone (Radicava) in the context of ALS (Amyotrophic Lateral Sclerosis) as of 2026. The field evolves rapidly — this is a research summary, not medical advice. Consult your neurologist or ALS specialist for personalized guidance.

Compound Overview

Edaravone (Radicava) (Free Radical Scavenger) — FDA-approved for ALS (2017)

Mechanism of action: Scavenges free radicals; reduces oxidative stress in motor neurons; IV administration required

Current evidence level: FDA-approved; RCT showed 33% slowing of functional decline in select ALS patients

2026 Research Landscape

Research has directly examined Edaravone (Radicava) in ALS, making this a field with active scientific interest.

Key areas researchers are currently examining include:

  • Mechanistic studies: Understanding precisely how Edaravone (Radicava) affects the biological pathways involved in ALS (Amyotrophic Lateral Sclerosis) progression
  • Safety characterization: Defining appropriate doses and monitoring protocols if clinical use is considered
  • Biomarker identification: Finding measurable indicators that could predict which patients might respond
  • Clinical trials: Phase I/II investigations examining Edaravone (Radicava) in ALS patients are ongoing or recently completed

Where to Find the Most Current Research

To access the latest peer-reviewed publications:

  • PubMed: Search "(Edaravone (Radicava)[tiab]) AND (ALS (Amyotrophic Lateral Sclerosis)[tiab])" at pubmed.ncbi.nlm.nih.gov
  • ClinicalTrials.gov: Search for active and completed trials with Edaravone (Radicava) keywords
  • Google Scholar: Sort by date for most recent publications

Research Gaps

The most significant gaps in the Edaravone (Radicava) + ALS research landscape as of 2026 include: lack of large Phase III randomized trials, limited long-term safety data in ALS patients, and absence of biomarker-selected patient populations who might benefit most.

Medical Disclaimer: This page summarizes published research and is not medical advice. Never start, stop, or change any treatment based on information found online. Always consult qualified healthcare professionals before making treatment decisions.

Get a personalized AI-generated research report at insightswarm.ai.

Frequently Asked Questions

What are the most recent studies on Edaravone (Radicava) for ALS?

The most current peer-reviewed studies can be found on PubMed (pubmed.ncbi.nlm.nih.gov). Search for 'Edaravone (Radicava) ALS (Amyotrophic Lateral Sclerosis)' filtered to the last 2 years. The current evidence level is: FDA-approved; RCT showed 33% slowing of functional decline in select ALS patients.

Are there any 2025-2026 clinical trials for Edaravone (Radicava) in ALS?

Check ClinicalTrials.gov with 'Edaravone (Radicava)' as intervention and 'ALS (Amyotrophic Lateral Sclerosis)' as condition. Filter by 'Recruiting' status for currently enrolling trials. Your neurologist or ALS specialist can advise whether any trials may be appropriate for your specific situation.

Has the evidence for Edaravone (Radicava) in ALS changed recently?

The field evolves rapidly. The current evidence classification is: FDA-approved; RCT showed 33% slowing of functional decline in select ALS patients. For the most up-to-date summary, Insight Swarm generates personalized research reports that incorporate the latest publications specific to your case.